Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

  • End date
    Sep 15, 2021
  • participants needed
  • sponsor
    Idorsia Pharmaceuticals Ltd.
Updated on 2 December 2020
antinuclear antibody


The purpose of the study is to assess the efficacy and safety of 4 doses of cenerimod versus placebo in adult subjects with systemic lupus erythematosus (SLE).


This is a Phase 2b, multicenter, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 4 doses of cenerimod versus placebo in adult subjects with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE).

Approximately 500 adult subjects with SLE will be randomized in a 1:1:1:1:1 ratio to placebo, 0.5, 1, 2, or 4 mg o.d. of cenerimod, in addition to background SLE therapy.

Treatment Placebo, Cenerimod 0.5 mg, Cenerimod 1 mg, Cenerimod 2 mg, Cenerimod 4 mg
Clinical Study IdentifierNCT03742037
SponsorIdorsia Pharmaceuticals Ltd.
Last Modified on2 December 2020

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.


Yes No Not Sure

Inclusion Criteria

Is your age between 18 yrs and 75 yrs?
Gender: Male or Female
Do you have any of these conditions: CONNECTIVE TISSUE DISEASE or Autoimmune disease or Dermatomyositis (Connective Tissue Disease) or SYSTEMIC LUPUS ERYTHEMATOSUS or Connective Tissue Di...?
Signed ICF prior to any study-mandated procedure
Diagnosis of SLE made at least 6 months prior to Screening, by fulfilling at least 4 of the 11 criteria for SLE as defined by the American College of Rheumatology (ACR) criteria
A mSLEDAI-2K score 6 of at least 2 points for musculoskeletal or mucocutaneous manifestations (i.e., myositis, arthritis, rash, alopecia, mucosal ulcers)
Currently treated with stable doses of one or more of the following background
Anti-malarials ( 400 mg/day hydroxychloroquine, 500 mg/day chloroquine, 100 mg/day quinacrine)
Mycophenolate mofetil ( 2 g/day)
Mycophenolic acid ( 1440 mg/day)
Azathioprine ( 2 mg/kg/day)
Methotrexate ( 20 mg/week)
Corticosteroids ( 40 mg/day prednisone or equivalent)
Belimumab (10 mg/kg every 4 weeks intravenously, or 200 mg/week subcutaneously)
History or presence of positive autoantibodies measured by central laboratory defined as follows: (a) Positive antinuclear antibody (ANA) test measured by immunofluorescence assay (IFA) with titre 1:80; AND/OR (b) positive anti-double stranded deoxyribonucleic acid (antidsDNA) antibodies with titre 30 IU/mL
Women of childbearing potential
Must have a negative serum pregnancy test at Screening
Must agree to undertake monthly urine pregnancy tests during the study
Must use highly effective methods of contraception from the screening visit until 4 months after taking the last dose of study treatment

Exclusion Criteria

Active lupus nephritis or a renal biopsy demonstrating immune complex mediated glomerulonephritis compatible with lupus nephritis
CNS lupus and severe forms of vasculitis requiring systemic immunosuppressive treatment
A diagnosis of mixed connective tissue disease or any history of overlap syndromes of SLE with rheumatoid arthritis, erosive arthritis, scleroderma or autoimmune hepatitis
History or presence of Mobitz type II or third-degree atrioventricular block, sick sinus syndrome, symptomatic bradycardia or syncope associated with cardiac disorders
Subjects who experienced myocardial infarction, unstable angina pectoris, stroke, transient ischemic attack, vascular thrombosis, decompensated heart failure requiring hospitalization, or heart failure defined by the New York Heart Association Class III/IV within six months prior to Screening
An elevated QT corrected for HR on the basis of Fridericia's formula interval of > 470 ms (females) / > 450 ms (males)
History or presence of severe respiratory disease or pulmonary fibrosis
Active or latent tuberculosis
Ongoing bacterial, viral or fungal infection that is of clinical concern in the judgment of the investigator or history of any serious infection
Subjects who have congenital or acquired severe immunodeficiency or known HIV infection or positive HIV testing
Presence of macular edema or active uveitis
Type 1 or 2 diabetes that is poorly controlled according to investigator judgment, or diabetes complicated with organ involvement such as diabetic nephropathy or retinopathy
Significant hematology abnormality: Lymphocyte count < 800 /L (0.8 10e9/L); hemoglobin < 9 g/dL; WBC count < 2500/L (2.5 10e9/L) or platelets < 75000/L (75 10e9/L)
Estimated glomerular filtration rate < 60 mL/min/1.73 m2
Known allergy to S1P receptor modulators or any of the cenerimod formulation excipients
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.
Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more
Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more
Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer


user name

Annotated by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No made yet